Literature DB >> 31325344

Human gestational N-methyl-d-aspartate receptor autoantibodies impair neonatal murine brain function.

Betty Jurek1,2, Mariya Chayka1,2, Jakob Kreye1,2, Katharina Lang1,2, Larissa Kraus1,3,4, Pawel Fidzinski1,3, Hans-Christian Kornau2,5, Le-Minh Dao1,2, Nina K Wenke2, Melissa Long6, Marion Rivalan6, York Winter6, Jonas Leubner1, Julia Herken1, Simone Mayer7, Susanne Mueller1,8,9, Philipp Boehm-Sturm1,8,9, Ulrich Dirnagl1,2,9, Dietmar Schmitz2,5,10, Michael Kölch11, Harald Prüss1,2,12.   

Abstract

OBJECTIVE: Maternal autoantibodies are a risk factor for impaired brain development in offspring. Antibodies (ABs) against the NR1 (GluN1) subunit of the N-methyl-d-aspartate receptor (NMDAR) are among the most frequently diagnosed anti-neuronal surface ABs, yet little is known about effects on fetal development during pregnancy.
METHODS: We established a murine model of in utero exposure to human recombinant NR1 and isotype-matched nonreactive control ABs. Pregnant C57BL/6J mice were intraperitoneally injected on embryonic days 13 and 17 each with 240μg of human monoclonal ABs. Offspring were investigated for acute and chronic effects on NMDAR function, brain development, and behavior.
RESULTS: Transferred NR1 ABs enriched in the fetus and bound to synaptic structures in the fetal brain. Density of NMDAR was considerably reduced (up to -49.2%) and electrophysiological properties were altered, reflected by decreased amplitudes of spontaneous excitatory postsynaptic currents in young neonates (-34.4%). NR1 AB-treated animals displayed increased early postnatal mortality (+27.2%), impaired neurodevelopmental reflexes, altered blood pH, and reduced bodyweight. During adolescence and adulthood, animals showed hyperactivity (+27.8% median activity over 14 days), lower anxiety, and impaired sensorimotor gating. NR1 ABs caused long-lasting neuropathological effects also in aged mice (10 months), such as reduced volumes of cerebellum, midbrain, and brainstem.
INTERPRETATION: The data collectively support a model in which asymptomatic mothers can harbor low-level pathogenic human NR1 ABs that are diaplacentally transferred, causing neurotoxic effects on neonatal development. Thus, AB-mediated network changes may represent a potentially treatable neurodevelopmental congenital brain disorder contributing to lifelong neuropsychiatric morbidity in affected children. ANN NEUROL 2019;86:656-670.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31325344     DOI: 10.1002/ana.25552

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  CSF Brain-Reactive Autoantibodies are Elevated in Patients with Viral Encephalitis.

Authors:  Zhong-Yuan Yu; Jian-Hong Wang; Wei-Wei Li; Ye-Ran Wang; Noralyn B Mañucat-Tan; Jun Wang; Ju Wang; Gao-Yu Cui; Jie-Xiang Pan; Shui-Xian Zhang; Zu-Juan Liu; Liang Tan; Yu-Hui Liu
Journal:  Neurosci Bull       Date:  2020-04-30       Impact factor: 5.203

Review 2.  Maternal Immune Dysregulation and Autism-Understanding the Role of Cytokines, Chemokines and Autoantibodies.

Authors:  Janna McLellan; Danielle H J Kim; Matthew Bruce; Alexandra Ramirez-Celis; Judy Van de Water
Journal:  Front Psychiatry       Date:  2022-06-02       Impact factor: 5.435

Review 3.  Autoantibodies in neurological disease.

Authors:  Harald Prüss
Journal:  Nat Rev Immunol       Date:  2021-05-11       Impact factor: 53.106

Review 4.  Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry.

Authors:  Niels Hansen; Daniel Luedecke; Berend Malchow; Michael Lipp; Jonathan Vogelgsang; Charles Timäus; Tristan Zindler; Stefan Gingele; Simone Kühn; Jürgen Gallinat; Klaus Wiedemann; Johannes Denk; Nicole Moschny; Jens Fiehler; Thomas Skripuletz; Christian Riedel; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Luise Poustka; Anne Karow; Hans Hartmann; Helge Frieling; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi
Journal:  J Neural Transm (Vienna)       Date:  2021-05-31       Impact factor: 3.575

5.  Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?

Authors:  Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Ann Neurol       Date:  2019-09-18       Impact factor: 10.422

Review 6.  Autoimmune encephalitis in children and adolescents.

Authors:  C G Bien; C I Bien
Journal:  Neurol Res Pract       Date:  2020-01-03

7.  Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms.

Authors:  Melanie Ramberger; Antonio Berretta; Jeanne M M Tan; Bo Sun; Sophia Michael; Tianrong Yeo; Jakob Theorell; Rachael Bashford-Rogers; Sofija Paneva; Victoria O'Dowd; Neesha Dedi; Sarfaraj Topia; Robert Griffin; Jorge Ramirez-Franco; Oussama El Far; Stéphanie Baulac; Maria I Leite; Arjune Sen; Alexander Jeans; David McMillan; Diane Marshall; Daniel Anthony; Daniel Lightwood; Patrick Waters; Sarosh R Irani
Journal:  Brain       Date:  2020-06-01       Impact factor: 15.255

8.  Pregnancy outcomes in anti-NMDA receptor encephalitis: Case series.

Authors:  Bastien Joubert; Anna García-Serra; Jesús Planagumà; Eugenia Martínez-Hernandez; Andrea Kraft; Frederick Palm; Takahiro Iizuka; Jérôme Honnorat; Frank Leypoldt; Francesc Graus; Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-01-16

Review 9.  Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk.

Authors:  Adrianna P Kępińska; Conrad O Iyegbe; Anthony C Vernon; Robert Yolken; Robin M Murray; Thomas A Pollak
Journal:  Front Psychiatry       Date:  2020-02-26       Impact factor: 4.157

10.  Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita.

Authors:  Ester Coutinho; Leslie Jacobson; Anthony Shock; Bryan Smith; Anthony Vernon; Angela Vincent
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.